Cite
HARVARD Citation
Williams, F. et al. (n.d.). Six versus three-weekly pembrolizumab: as well-tolerated?. Lung cancer. pp. S11-S12. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Williams, F. et al. (n.d.). Six versus three-weekly pembrolizumab: as well-tolerated?. Lung cancer. pp. S11-S12. [Online].